ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel GIP, GLP-1, and receptor in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Retatrutide (GLP-3): The Triple Agonist

DAmico AM, Li TT, Wylie D, Wang G, Vasquez KM

These molecules create what can be likened to cellular rust, similar to the rusting of iron when exposed to harsh environmental conditions

Interferon, dacarbazine, and BCG have been tried with marginal and unpredictable results

J Urol 97 : 874875 Montorsi F et al

In a dose escalation study of ADI-EGP20 together with cisplatin and pemetrexed in thoracic cancer patients, sustainable arginine depletion was observed in all patients and neutralizing antibodies level was much lower compared to ADI-PEG20 mono therapy or ADI-PEG20, docetaxel combinational therapy [143]

Someone might say "I take 25 units of tirzepatide" and mean 2.5 mg (from a 10 mg/mL vial)